NASDAQ:DNTH Dianthus Therapeutics Q1 2026 Earnings Results & Report $77.58 -3.99 (-4.89%) Closing price 10/13/2026 04:00 PM EasternExtended Trading$77.63 +0.05 (+0.06%) As of 10/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Dianthus Therapeutics beat analyst expectations on both earnings and revenue in its Q1 2026 results, released May 5, 2026. The company reported EPS of -$0.85 versus the -$1.0719 consensus estimate, while revenue of $0.46 million topped the $0.40 million estimate by $0.06 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 5, 2026TimeAfter Market ClosesConference Call4:00 PM ET Dianthus Therapeutics EPS ResultsActual EPS-$0.85Consensus EPS -$1.0719Beat/MissBeat by +$0.2219One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersDianthus Therapeutics Revenue ResultsActual Revenue$0.46 millionExpected Revenue$0.40 millionBeat/MissBeat by +$59.00 thousandYoY Revenue GrowthN/AUpcoming EarningsDianthus Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 4, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Dianthus Therapeutics Q1 2026 Earnings FAQ Did Dianthus Therapeutics beat earnings estimates for Q1 2026? Dianthus Therapeutics (NASDAQ:DNTH) reported earnings of -$0.85 per share for Q1 2026, beating the consensus estimate of -$1.0719. The report was announced on Tuesday, May 5, 2026. What was Dianthus Therapeutics' revenue for Q1 2026? Dianthus Therapeutics reported revenue of $0.46 million for Q1 2026, against a consensus estimate of $0.40 million. When is Dianthus Therapeutics' next earnings date? Dianthus Therapeutics' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Dianthus Therapeutics on the company's earnings history page. Dianthus Therapeutics Earnings HeadlinesDianthus Therapeutics Recognized Among Fortune’s 2026 Best Workplaces In BioPharmaOctober 13 at 1:28 PM | markets.businessinsider.comDianthus Therapeutics Named to Fortune’s 2026 Best Workplaces in BioPharma List Amid Company ExpansionOctober 13 at 1:28 PM | finance.yahoo.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country. | Banyan Hill Publishing (Ad)Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharmaOctober 13 at 8:45 AM | globenewswire.comH.C. Wainwright Reaffirms Their Buy Rating on Dianthus Therapeutics (DNTH)October 12 at 7:53 PM | theglobeandmail.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Stock Rated "Moderate Buy" by Wall Street BrokeragesOctober 8, 2026 | americanbankingnews.comSee More Dianthus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Dianthus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dianthus Therapeutics and other key companies, straight to your email. Email Address About Dianthus TherapeuticsDianthus Therapeutics (NASDAQ:DNTH) is a clinical-stage biotechnology company focused on developing targeted antibody therapies for autoimmune diseases. The company’s approach centers on selectively modulating the complement system, an immune pathway involved in inflammation and tissue damage, with the goal of creating treatments that may offer potent disease control and convenient dosing. Dianthus’ lead investigational product is DNTH103, a fully human monoclonal antibody designed to selectively inhibit activated C1s, a key protein in the classical complement pathway. DNTH103 is engineered for extended activity and subcutaneous administration and is being evaluated in immune-mediated neuromuscular and neurological disorders, including generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. The company is also advancing additional complement-targeted programs for autoimmune diseases. Dianthus serves global markets through its clinical development activities and is headquartered in the United States. As a development-stage biotechnology company, its products remain investigational and are subject to clinical testing and regulatory review before they may become commercially available.View Dianthus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
